Therapy Analysis

Delivering innovative research
to the therapy analysis market
Identifying and commercializing
first-in-class innovation in early stage development
Thought provoking insights
covering hot topics and key industry issues
Providing specialty research and data
to the devices and diagnostics industries

Research Services

GBI Research provides intelligence from high-growth therapy areas and novel drug treatments to pioneering companies and their strategies

Research Services

Therapy Analysis

You are here:

Research Services >

Therapy Analysis

GBI Research’s core pharmaceutical service is Therapy Analysis. This is divided into global Strategic Assessment and region-specific APAC Markets modules. Strategic Assessments are focused at the therapy area level, while APAC markets are single-indication based reports. Both modules provide users with clear decision-support tools to better assess unmet needs, benchmark products, and assess trial attrition rates, in order to focus their products and R&D programs on areas of need.

Strategic Assessment

Therapy Analysis - Strategic Assessment is a report format providing a scientifically robust assessment of treatment options and late-stage pipeline development within a particular therapy area. This is combined with an innovative commercial focus on market forecasting, and licensing and co-development deals analysis

GBI Research’s Therapy Analysis: Strategic Assessment reports provide a global market and pipeline assessment, aimed at a senior strategy/planning audience.
The reports provide crucial information and contextual understanding about opportunities in secondary and associated disease areas.
Leveraging high-quality proprietary databases, extensive literature reviews and expert analyst commentary, the elements of each report combine to build a comprehensive and meaningful analysis of a disease area.
Each report contains an extensive disease area overview, and epidemiology research detailing the etiology, epidemiology, diagnostic techniques, disease staging and typical prognoses. A general overview is provided, in addition to more granular analysis of three to five key indications.
A clinical and commercial assessment of the currently available marketed products and the level of unmet need is provided.
Market size and forecasting data is provided, including single product forecasting for high-profile pipeline products. This includes an analysis of generic share, a split by product groups, and forecasts for key companies and pipeline products.
Forecast data are built on an innovative multi-scenario forecasting model, taking into consideration a wide range of factors, acknowledging the uncertainty in the market and providing an understanding of the scale of variation that this implies.
The reports contain company analysis that provides a clear view of the strategic positioning of the key companies within the therapy area, to supplement the company-level revenue and market share forecasts provided in the earlier market forecast.
Licensing and co-development deals analysis is provided, providing important contextual information for companies involved in or looking at opportunities within the disease area.

APAC Markets

Therapy Analysis – APAC Markets is a report format focusing specifically on the important Asia-Pacific markets of Japan, India, China, South Korea and Australia. Reports provide single-indication coverage of treatment options, and analysis of late-stage pipeline development, together with an innovative commercial focus on market forecasting and licensing/co-development deals analysis.

Leveraging high-quality proprietary databases and expert analyst commentary, the elements of each report combine to build a comprehensive and meaningful analysis of a specific indication.
Each report contains an extensive disease overview, and epidemiology research detailing the etiology, epidemiology, diagnostic techniques, disease staging and typical prognoses. Analysis of current treatment options and algorithms is also provided.
A clinical and commercial assessment of the currently available marketed products and the level of unmet need is provided.
Each report includes an innovative examination of the products in pipeline development, covering their profiles and clinical trial performance benchmarked against marketed products. This includes extensive data analysis, enabling risk assessment and profiling.
Market size and forecasting data are provided, including single-product forecasting for high-profile pipeline products.
Forecast data are built on an innovative epidemiology-based multi-scenario forecasting model, taking into consideration a wide range of factors, acknowledging the uncertainty in the market and providing an understanding of the scale of variation that this implies.
Licensing and co-development deals analysis is provided, providing important contextual information for companies involved in or looking at opportunities within the area.